Showing 1 - 10 of 591
Persistent link: https://www.econbiz.de/10010515278
Persistent link: https://www.econbiz.de/10011297627
We study the impact of exposing hospitals in a National Health Service (NHS) to non-price competition by exploiting a patient choice reform in Norway in 2001. The reform facilitates a difference-in-difference research design due to geographical variation in the scope for competition. Using rich...
Persistent link: https://www.econbiz.de/10012906335
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmaceutical market. For given prices, RP increases generic firms' expected profit, but since RP also stimulates price competition, the impact on generic entry is theoretically ambiguous. In order to...
Persistent link: https://www.econbiz.de/10013021208
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10013285854
Persistent link: https://www.econbiz.de/10013191490
Persistent link: https://www.econbiz.de/10011589279
Persistent link: https://www.econbiz.de/10011950419
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10014080046
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10013353465